Helix BioPharma Corp., a clinical-stage oncology company focused on developing therapies for difficult-to-treat cancers, has announced immediate changes to its Board of Directors. Janusz Grabski has resigned from the board, and Thomas Mehrling, M.D., Ph.D., the company's Chief Executive Officer, has been appointed as a director. This appointment follows the board nomination right granted to Laevoroc Immunology AG in connection with Helix's 2025 acquisition of substantially all of the assets of Laevoroc Immunology AG and Laevoroc Chemotherapy AG.
The changes are intended to ensure that the board continues to meet Helix's evolving governance and capital markets requirements. The company emphasizes that the new composition brings the experience needed to support its clinical development and broader corporate objectives. The board expressed gratitude to Mr. Grabski for his service and contributions, wishing him success in his future endeavors.
Helix BioPharma is advancing a pipeline led by L-DOS47, a clinical-stage antibody-enzyme conjugate being developed as a combination therapy for non-small cell lung cancer (NSCLC). Additional candidates include LEUMUNA™, a pre-IND oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA™, a pre-IND gemcitabine prodrug for advanced solid tumors. The company's focus remains on addressing underserved patient populations with difficult-to-treat cancers.
The board changes come at a critical time as Helix continues to progress its clinical programs and seeks to strengthen its position in the oncology space. The appointment of Dr. Mehrling, who also serves as CEO, is seen as a move to align leadership with the company's strategic direction. This integration of roles may enhance decision-making efficiency and reinforce the company's commitment to its pipeline.
Helix's common shares are listed on the Toronto Stock Exchange (TSX: HBP), quoted on the OTC Pink Market (HBPCD), and listed on the Frankfurt Stock Exchange (FWB: HBP0). For more information about the company and its recent acquisition, visit Helix's announcement on the Laevoroc acquisition. The company's website provides further details on its pipeline and corporate governance.
